Immix Biopharma, Inc. (IMMX)
- Previous Close
2.1300 - Open
2.1500 - Bid 2.0700 x 100
- Ask 2.1900 x 100
- Day's Range
2.0200 - 2.2899 - 52 Week Range
1.4000 - 7.7500 - Volume
53,122 - Avg. Volume
262,461 - Market Cap (intraday)
55.696M - Beta (5Y Monthly) 0.05
- PE Ratio (TTM)
-- - EPS (TTM)
-0.8900 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
14.00
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and immune-dysregulated diseases in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and colorectal cancer; and NXC-201 for relapsed/refractory multiple myeloma. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. Immix Biopharma, Inc., was incorporated in 2012 and is headquartered in Los Angeles, California.
www.immixbio.comRecent News: IMMX
Performance Overview: IMMX
Trailing total returns as of 4/25/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: IMMX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: IMMX
Valuation Measures
Market Cap
56.22M
Enterprise Value
37.21M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
3.43
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
-2.39
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-57.92%
Return on Equity (ttm)
-106.23%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-15.43M
Diluted EPS (ttm)
-0.8900
Balance Sheet and Cash Flow
Total Cash (mrq)
17.51M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-5.94M
Research Analysis: IMMX
Company Insights: IMMX
Fair Value
Dividend Score
Hiring Score
Insider Sentiment Score
Research Reports: IMMX
Daily – Vickers Top Buyers & Sellers for 12/13/2023
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Daily – Vickers Top Insider Picks for 11/20/2023
The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.
Daily – Vickers Top Insider Picks for 10/30/2023
The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.
Daily – Vickers Top Insider Picks for 10/27/2023
The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.